ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS' landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-2026;